King Chuen Li

Title: King Chuen Li: A Pioneer in Multivalent Integrin Antagonist Compounds

Introduction

King Chuen Li, based in Houston, TX, is a distinguished inventor with a total of three patents to his name. His innovative work primarily focuses on integrin antagonist compounds, which have significant implications in therapeutic treatments and diagnostic methods.

Latest Patents

Li’s latest patents include groundbreaking advancements such as "Labeled, non-peptidic, multivalent integrin antagonist compounds; methods for synthesis and uses thereof." This patent discloses multivalent integrin-receptor antagonists that can be utilized in various therapeutic, prophylactic, and diagnostic imaging modalities. The compounds presented have been prepared for applications in the detection and imaging of biological samples, particularly noting their utility in combating proliferative diseases like cancer. Furthermore, the compounds include fluorescently or radio-labeled non-peptidic multivalent integrin alpha-beta compounds, which provide potential in detecting and localizing cancer cells in vitro, in vivo, and in situ.

Another notable patent authored by Li is “Containment tubes and imaging systems employing same.” This invention outlines an innovative isolation system equipped with imaging or radiation therapy capabilities. The design features a containment barrier that creates an isolation region, allowing for effective imaging or therapy while preventing contamination. This method enhances the communication between the imaging or therapy system and the internal environment, offering advanced solutions in medical technology.

Career Highlights

Throughout his career, King Chuen Li has contributed significantly to the fields of medical imaging and cancer treatment. He has worked with reputable organizations such as Koninklijke Philips Corporation N.V. and The Methodist Hospital Research Institute, further demonstrating his commitment to advancing healthcare technology through innovative solutions.

Collaborations

Li has collaborated with esteemed colleagues such as Alan Love and Zheng Li, contributing to molecular and imaging research that has led to the development of his patented technologies. These collaborations emphasize the importance of teamwork and multidisciplinary approaches in the successful transition from conceptualization to practical application of inventions.

Conclusion

King Chuen Li exemplifies the spirit of innovation in the field of integrin antagonist compounds, demonstrating exceptional proficiency in developing novel therapeutics that hold promise for cancer treatment and diagnosis. His continued contributions to research and development mark him as a vital figure in advancing medical science and improving patient outcomes.